(+)-JQ1

For research use only.

Catalog No.S7110

237 publications

(+)-JQ1 Chemical Structure

CAS No. 1268524-70-4

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's (+)-JQ1 has been cited by 237 publications

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MlfJR4VtdCCYaXHibYxqfHliQYPzZZk> M{nQelI2OC93MECvNVAxOCCwTR?= M2TsdVI1NzR6L{eyJIg> NWjvR2kxTE2VTx?= NWPGZ5pUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? MViyOlcxPzh6MR?=
BCPAP NVHJbId{S2WubDDWbYFjcWyrdImgRZN{[Xl? MVuyOVAwPTByL{GwNFAhdk1? M2frclI1NzR6L{eyJIg> MXXEUXNQ Mn;RbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NHz0e5gzPjdyN{i4NS=>
K1  M4jSTWNmdGxiQ4njcIUhSXO|YYm= NYnmempTOjVyL{WwNE8yODByIH7N MnnYO|IhcA>? NUTlTopXTE2VTx?= MmDTZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NHrWNFkzPjdyN{i4NS=>
BCPAP MUXD[YxtKEO7Y3zlJGF{e2G7 MlLHNlUxNzVyMD:xNFAxKG6P M3\ZTFczKGh? MUTEUXNQ NHTCR5JienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= MkjrNlY4ODd6OEG=
Hep3B Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\YeVAuOTBizszN NV:zWJlIPSCm MlS5SG1UVw>? M4nheWlEPTB;MD6wPEDPxE1? M4S3UlI3PTd3MU[3
HCCLM3 M3XGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDuNE0yOCEQvF2= MnO3OUBl NUHTZ|VTTE2VTx?= MofhTWM2OD1yLkG0JO69VQ>? Mo\TNlY2PzVzNke=
HuH7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T0elAuOTBizszN MX61JIQ> NXzhTFlXTE2VTx?= NVGze|BNUUN3ME2wMlIyKM7:TR?= NG\VcZQzPjV5NUG2Oy=>
HepG2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUew[FA2OC1zMDFOwG0> NXf6coQ6PSCm NECwOWlFVVOR Ml;zTWM2OD1yLkO0JO69VQ>? NGPUfpczPjV5NUG2Oy=>
SMMC7721 M{PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonUNE0yOCEQvF2= NWr4UZJIPSCm NVGwNVVPTE2VTx?= NFLKbZdKSzVyPUCuOFEh|ryP MlHFNlY2PzVzNke=
BEL7402 NWXWXpV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDmNE0yOCEQvF2= NHjYc|U2KGR? MWTEUXNQ MYfJR|UxRTBwNEeg{txO MXWyOlU4PTF4Nx?=
MHCC97H MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX1dFYxNTFyIN88US=> NXmwZnF7PSCm MU\EUXNQ MXPJR|UxRTBwNEGg{txO MWKyOlU4PTF4Nx?=
Hep3B Mof5R4VtdCCFeXPs[UBCe3OjeR?= MYqwMlEwOC53L{KuOUDPxE1? Ml3COFghcA>? NHTzSIVFVVOR M{DwSoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NH\4bGgzPjV5NUG2Oy=>
HCCLM3 M3XwWmNmdGxiQ4njcIUhSXO|YYm= NFzDZmwxNjFxMD61M|IvPSEQvF2= MlLkOFghcA>? NGTwTlBFVVOR NIraXm5t\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? NIT1NmkzPjV5NUG2Oy=>
Hep3B NVfrXmJ{SXCxcITvd4l{KEG|c3H5 MkfBNE4yNzBwNT:yMlUh|ryP M1X3eVQ5KGh? NITESnlFVVOR MYXhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli NV;xSnFoOjZ3N{WxOlc>
HCCLM3 Mln0RZBweHSxc3nzJGF{e2G7 NGjkfpkxNjFxMD61M|IvPSEQvF2= M1S0WFQ5KGh? NGrqS4NFVVOR MUHhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli MUWyOlU4PTF4Nx?=
A549 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDBVI0xNjFvMUCg{txO NYLHZnF3PzJiaB?= M4DtVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYDM[ZdmOjZ2MUWyNlU>
H157 NVm2bWRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPBVncxNjFvMUCg{txO MoXxO|IhcA>? NGTkdZRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmPwNlY1OTV{MkW=
H1299 NWW3cJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr4PXMxNjFvMUCg{txO M4fBTlczKGh? MoX6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MX2yOlQyPTJ{NR?=
A549 NInHbm1HfW6ldHnvckBCe3OjeR?= NULLRpZ7OS9{LkWvOUDPxE1? NEjGV48yOiCq MXRCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ MYKyOlQyPTJ{NR?=
H1299 MWnGeY5kfGmxbjDBd5NigQ>? NHS4S4gyNzJwNT:1JO69VQ>? MXmxNkBp NHSyVo/DqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| M2DNOFI3PDF3MkK1
H157 NIPOem1HfW6ldHnvckBCe3OjeR?= M3Hve|EwOi53L{Wg{txO MWexNkBp NVThb4t3\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u NEjRR24zPjRzNUKyOS=>
H1299 NEXTNHhHfW6ldHnvckBCe3OjeR?= NFHhR4YyNzJwNT:1JO69VQ>? NIDKclMyOiCq NGnTXWdl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= MWmyOlQyPTJ{NR?=
C8161 NVq3blh2S2WubDDWbYFjcWyrdImgRZN{[Xl? MXWwMVIh|ryP MljDOEBl MXLEUXNQ NWnyOVZq\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3jHTFI3Ozl5MkKz
Mel285 NIDCSmpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX3ofIRuOC1{IN88US=> MYq0JIQ> NFTue21FVVOR M{jPboRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGe3WFgzPjN7N{KyNy=>
Mel290 NXHJPJZlS2WubDDWbYFjcWyrdImgRZN{[Xl? MVSwMVIh|ryP M4fEUFQh\A>? MXXEUXNQ MmTy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkHDNlY{QTd{MkO=
92.1 M1vvOWNmdGxiVnnhZoltcXS7IFHzd4F6 NVfmV25XOC1{IN88US=> M1TKTVQh\A>? MXXEUXNQ NIn6UWNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF;yT3ozPjN7N{KyNy=>
Omm1.3 MnrzR4VtdCCYaXHibYxqfHliQYPzZZk> MXOwMVIh|ryP M2\kcVQh\A>? NXjaXJRpTE2VTx?= MXHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{D3cFI3Ozl5MkKz
Mel202 M13pS2NmdGxiVnnhZoltcXS7IFHzd4F6 NEi5NIExNTJizszN MVO0JIQ> NUjhOpJSTE2VTx?= NEXOZXdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NH:0RVUzPjN7N{KyNy=>
Mel270 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXOwMVIh|ryP NG[yc3Q1KGR? NVi5PIsyTE2VTx?= MXPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF;pfYczPjN7N{KyNy=>
Omm1 NXLTdZR4S2WubDDWbYFjcWyrdImgRZN{[Xl? NF\iVIoxNTJizszN MV60JIQ> NVfVVZpyTE2VTx?= MV\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYrR[mVYOjZ|OUeyNlM>
92.1 MnXjRZBweHSxc3nzJGF{e2G7 NV7NdHMxPTByIH7N M3vkbVQ5KGh? NEToeFFFVVOR Mnz5bY5lfWOnczDhdI9xfG:|aYO= NHG0b4wzPjN7N{KyNy=>
Omm1.3 MXzBdI9xfG:|aYOgRZN{[Xl? MV21NFAhdk1? MVO0PEBp M4TGbmROW09? NWTaN2hkcW6mdXPld{BieG:ydH;zbZM> Mn3NNlY{QTd{MkO=
92.1 NWSweGU4S2WubDDDfYNt\SCDc4PhfS=> MUK1NFAhdk1? MlP1NlQwPDhxN{KgbC=> MVLEUXNQ NUDrZZFKcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= MVmyOlM6PzJ{Mx?=
Omm1.3 NFfsTHlE\WyuIFP5Z4xmKEG|c3H5 NFnjWVM2ODBibl2= M4rCR|I1NzR6L{eyJIg> MV\EUXNQ MYDpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NHPEN3ozPjN7N{KyNy=>
A549 MUjGeY5kfGmxbjDBd5NigQ>? NGXCcXYyODBxNECwM|ExODBibl2= MYKyOEBp NILJXox2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz Ml7GNlYzOTJzOUm=
MCF-7 M{O5dmZ2dmO2aX;uJGF{e2G7 NGHYRWUyODBxNECwM|ExODBibl2= M1\EWFI1KGh? NWr2bGlFfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= Mmf0NlYzOTJzOUm=
HEK293 NYSxU|NCTnWwY4Tpc44hSXO|YYm= MWmxNFAwPDByL{GwNFAhdk1? MXGyOEBp MVr1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy M2DGSFI3OjF{MUm5
858 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnPINE0yKM7:TR?= MV61JIQ> NYTnUJQ{TE2VTx?= NIr4b41l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmTYNlYzODZ|M{O=
DDR2L63V M3\4V2NmdGxiVnnhZoltcXS7IFHzd4F6 MorhNE0yKM7:TR?= MkH6OUBl MVfEUXNQ M{ezUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M37SfVI3OjB4M{Oz
BE(2)-C MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFnkZnkyKM7:TR?= M2HXV|EuPCCm MkPB[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> Ml7rNlYxPjd2NkS=
IMR-32 NWfXcmJXS2WubDDWbYFjcWyrdImgRZN{[Xl? MX2xJO69VQ>? NWn4VlM5OS12IHS= NWPn[mxJ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NYXZVJBHOjZyNke0OlQ>
JF MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkLKNUDPxE1? Mlf4NU01KGR? NIHVcXFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MVKyOlA3PzR4NB?=
BE(2)-M17 NVfUdohlS2WubDDWbYFjcWyrdImgRZN{[Xl? MVWxJO69VQ>? MXyxMVQh\A>? NU\NU41x\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MYmyOlA3PzR4NB?=
SK-N-SH MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkX4NUDPxE1? NXGwWm1[OS12IHS= M3vUV4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NH\ifXAzPjB4N{S2OC=>
SK-N-DZ  MonrR4VtdCCYaXHibYxqfHliQYPzZZk> NUPBPHpoOSEQvF2= NWrYRox3OS12IHS= NYOwe4pz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M2DoN|I3ODZ5NE[0
HMC-1.1  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[1MVUxODBibl2= MVS0PEBp NUXTbXhSTE2VTx?= M{nRfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3XVTFI3ODV3M{Cz
HMC-1.2 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXaPYkzPS13MECwJI5O MX60PEBp M{fUW2ROW09? NXjCW3h4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{Pie|I3ODV3M{Cz
ROSA KIT WT  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETZOY82NTVyMECgcm0> NHu5[lU1QCCq NVXLO41LTE2VTx?= NV\pbXJzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVuyOlA2PTNyMx?=
ROSA KIT D816V MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fVeFUuPTByMDDuUS=> NUD5TGNSPDhiaB?= M1K3S2ROW09? MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYrNcVRtOjZyNUWzNFM>
HMC-1.1  NH[yV4lCeG:ydH;zbZMhSXO|YYm= NUDFWVJ1OjByLUWwNFAhdk1? M3nPN|Q5KGh? M325UmROW09? NHewSVBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnjsNlYxPTV|MEO=
HMC-1.2 NFj6do5CeG:ydH;zbZMhSXO|YYm= Ml3CNlAxNTVyMECgcm0> NUHDSpplPDhiaB?= NHPTbppFVVOR MU\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NV;odnh7OjZyNUWzNFM>
ROSA KIT WT  MU\BdI9xfG:|aYOgRZN{[Xl? MWiyNFAuPTByMDDuUS=> NEnyPZc1QCCq NGP3XoZFVVOR MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2XPRlI3ODV3M{Cz
ROSA KIT D816V NXvvNHI3SXCxcITvd4l{KEG|c3H5 NX3SbWNOOjByLUWwNFAhdk1? NGX6bWs1QCCq NGHJOJZFVVOR NVnDXIJUcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWGyOlA2PTNyMx?=
494H M3myS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T5dFczKGh? NFe4TGNFVVOR MoTGTWM2OD1yLkGyNuKyOC5yMESg{txO MWiyOVk1PDV4Nh?=
493H NGf6emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[1O|IhcA>? M4jhTGROW09? M2joOGlEPTB;MD6wOFfDuTBwMEC5JO69VQ>? MYiyOVk1PDV4Nh?=
716H MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYO3NkBp M2XVeWROW09? M1jrUWlEPTB;MD6yNVLDuTBwMEO0JO69VQ>? MmTqNlU6PDR3Nk[=
148I NWX6bFBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jiUVczKGh? MlPHSG1UVw>? NHTuUVZKSzVyPUCuNlg1yrFyLkCzOUDPxE1? M2PrVFI2QTR2NU[2
98Sc MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX2UJhnPzJiaB?= MVzEUXNQ MlnqTWM2OD1yLkGxOeKyOC5yMESg{txO MUOyOVk1PDV4Nh?=
89R NX\ISGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUS3NkBp MXHEUXNQ MVzJR|UxRTBwMUK2xtExNjByMzFOwG0> MX2yOVk1PDV4Nh?=
494L M2XOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTRO|IhcA>? M3LFOmROW09? M32y[mlEPTB;MD6zNVfDuTBwMEGyJO69VQ>? NHX5[VAzPTl2NEW2Oi=>
493L MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzI[Ww4OiCq NYjV[HN2TE2VTx?= MVLJR|UxRTBwMEWwxtExNjBzMTFOwG0> NV6yd45TOjV7NES1OlY>
148L MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjFcpc4OiCq MY\EUXNQ MXXJR|UxRTBwMUS2xtExNjBzNzFOwG0> NYPNVmRDOjV7NES1OlY>
98L MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7sZZM4OiCq NXTLT5RuTE2VTx?= NHn0NWpKSzVyPUCuN|A6yrFyLkCyPUDPxE1? MWqyOVk1PDV4Nh?=
OS17 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ryXFczKGh? NGrKbZhFVVOR MnzLTWM2OD1yLkC3PeKyOC5yMEOg{txO MV[yOVk1PDV4Nh?=
OS9 M2m1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrHSG84OiCq M2HJd2ROW09? NYT4XFJUUUN3ME2wMlQxPsLzMD6wNlgh|ryP Mnu1NlU6PDR3Nk[=
MG63 NYrkeIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3odlZRPzJiaB?= NGTTeoNFVVOR NFHidWlKSzVyPUCuNVE1yrFyLkCyOUDPxE1? NYHSTlB1OjV7NES1OlY>
SAOS2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWyO|IhcA>? NH7kW2FFVVOR NWjYN5NnUUN3ME2wMlIyP8LzMD6wNFMh|ryP MXuyOVk1PDV4Nh?=
U2OS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLze4k4OiCq M2jUc2ROW09? M1PrW2lEPTB;MD6xPVjDuTBwMEC4JO69VQ>? NGn1[IkzPTl2NEW2Oi=>
SJSA-1 NEL4bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHpTHk4OiCq MmLoSG1UVw>? NWXKT4Q4UUN3ME2wMlExOMLzMD6wNVAh|ryP M3L6[FI2QTR2NU[2
494H MnnDRZBweHSxc3nzJGF{e2G7 NUToSWdXOC5{NT:wMlUwOS5yIN88US=> NWThd2l3OjRiaB?= M{SwWWROW09? NG\uPIJqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MVuyOVk1PDV4Nh?=
148I MojDRZBweHSxc3nzJGF{e2G7 MV2wMlI2NzBwNT:xMlAh|ryP NFrZZ4IzPCCq NUjSdHJyTE2VTx?= MljMbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh NEjle|UzPTl2NEW2Oi=>
OS17 MYTBdI9xfG:|aYOgRZN{[Xl? NV;SNYx[OC5{NT:wMlUwOS5yIN88US=> Mkj4NlQhcA>? MUXEUXNQ M4\reolv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NGHmb2MzPTl2NEW2Oi=>
494H M{HEVmFxd3C2b4Ppd{BCe3OjeR?= Mlu2NgKBkc7:TR?= MonXOFghcA>? MnywSG1UVw>? NXTx[5BzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MVOyOVk1PDV4Nh?=
148I NV;lUJFNSXCxcITvd4l{KEG|c3H5 MXex5qCK|ryP NInBN5A1QCCq M2DPSGROW09? MlPEbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NXf4U|VEOjV7NES1OlY>
OS17 M{X4OmFxd3C2b4Ppd{BCe3OjeR?= NFSxWZEy6oDLzszN NXfrclQ3PDhiaB?= Mk\kSG1UVw>? Mn64bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MYSyOVk1PDV4Nh?=
MOLM13 M2\NUmFxd3C2b4Ppd{BCe3OjeR?= Mn3WNlUxKG6P MkXKOFghcA>? NGLJPJJFVVOR MW\pcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? NVu4SGFXOjVyNUO4NlU>
MV4-11  M2HQXmFxd3C2b4Ppd{BCe3OjeR?= Mk\pNlUxKG6P MYe0PEBp NWTLV3ZuTE2VTx?= NGWzcnJqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= MYCyOVA2Ozh{NR?=
MOLM13 MWDGeY5kfGmxbjDBd5NigQ>? M3LoOVI2OCCwTR?= NGHtbmQzPCCq MUDEUXNQ M17rN4VvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= M4S0N|I2ODV|OEK1
MV4-11  NF;rW5hHfW6ldHnvckBCe3OjeR?= NWLOVGdMOjVyIH7N M4fnOVI1KGh? NW\3Vng6TE2VTx?= NFnCcHhmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= NVHQS4l5OjVyNUO4NlU>
MOLM13 M3rsNWFxd3C2b4Ppd{BCe3OjeR?= MoTpNlUxKG6P M4Hn[|Q5KGh? MWnEUXNQ NEPDeGRqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk M13kN|I2ODV|OEK1
MV4-11  M2fBWGFxd3C2b4Ppd{BCe3OjeR?= MYSyOVAhdk1? MlraOFghcA>? MoHESG1UVw>? MYDpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj NXKybGFQOjVyNUO4NlU>
Hela M1vnUWNmdGxiVnnhZoltcXS7IFHzd4F6 NV:5W41YOC13MECgcm0> MUe3NkBp NFL2UWpFVVOR MkfN[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVXhZldzOjVyMEmyPVU>
HBL-1 M2TBOGNmdGxiVnnhZoltcXS7IFHzd4F6 NYnzO4ZrOC13MECgcm0> NX\mdlJRPzJiaB?= MnPlSG1UVw>? MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHj0fpEzPTByOUK5OS=>
HLY-1 NHnxeXhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV\LS2s1OC13MECgcm0> NH;1cIg4OiCq NGL3W2hFVVOR MUfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXe3OW9kOjVyMEmyPVU>
OCI-Ly3 M2n6UGNmdGxiVnnhZoltcXS7IFHzd4F6 NEDhOIcxNTVyMDDuUS=> MYm3NkBp NVS3c5VFTE2VTx?= NXK5W2tF\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXvNUIRWOjVyMEmyPVU>
OCI-Ly10 M17tWmNmdGxiVnnhZoltcXS7IFHzd4F6 NFfjSYsxNTVyMDDuUS=> M3vSU|czKGh? NHvFe2tFVVOR MoDT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEPpdmUzPTByOUK5OS=>
SU-DHL-4 NX;CWo1sS2WubDDWbYFjcWyrdImgRZN{[Xl? MlPjNE02ODBibl2= NFfFO3Q4OiCq MknxSG1UVw>? MUHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYT4T5d3OjVyMEmyPVU>
SU-DHL-5 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3v1dVAuPTByIH7N MXi3NkBp MorUSG1UVw>? NEPzSZhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn[5NlUxODl{OUW=
SU-DHL-6 NV7xV5BIS2WubDDWbYFjcWyrdImgRZN{[Xl? NX7lcpQyOC13MECgcm0> MXq3NkBp NFPodW5FVVOR NIPxWINl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWDx[XdoOjVyMEmyPVU>
SU-DHL-10 M1XFNWNmdGxiVnnhZoltcXS7IFHzd4F6 NHrKdW8xNTVyMDDuUS=> M1\p[lczKGh? M2TVeWROW09? M{DX[YRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVmyOVAxQTJ7NR?=
RC-K8 MnfsR4VtdCCYaXHibYxqfHliQYPzZZk> M3m3OFAuPTByIH7N M1[0ZlczKGh? MoPuSG1UVw>? MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2GxR|I2ODB7Mkm1
OCI-Ly8 NWO3dGRmS2WubDDWbYFjcWyrdImgRZN{[Xl? NHXoWmUxNTVyMDDuUS=> M2nMTFczKGh? NVvmcZBRTE2VTx?= NHz1WlZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIfNbHczPTByOUK5OS=>
OCL-Ly18 M1nlO2NmdGxiVnnhZoltcXS7IFHzd4F6 NIfFZmkxNTVyMDDuUS=> M3vpblczKGh? NHj6dXZFVVOR NX\SZYtV\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHGyVFkzPTByOUK5OS=>
OCI-Ly3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TTNlE4Oi9{NUCvOVAxKG6P MV[yM|ch\A>? NGDMO4tFVVOR NVvpZZlVcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MV2yOVAxQTJ7NR?=
OCI-Ly8 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\TN3NnOTd{L{K1NE82ODBibl2= M{[xfFIwPyCm M{nwR2ROW09? NHu2dJhqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NHLkVm8zPTByOUK5OS=>
SU-DHL-4 NV:1N2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrtNVczNzJ3MD:1NFAhdk1? M4rhdVIwPyCm MoL0SG1UVw>? NYn6c5RocW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MV[yOVAxQTJ7NR?=
SU-DHL-10 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqxO|IwOjVyL{WwNEBvVQ>? M170d|IwPyCm MkHySG1UVw>? NGTmeYJqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MmnsNlUxODl{OUW=
OCI-Ly3 NHzKOHVCeG:ydH;zbZMhSXO|YYm= M2TiblE4Oi9{NUCgcm0> NEHFN2c4\A>? M1nTUGROW09? MXLpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= MVyyOVAxQTJ7NR?=
OCI-Ly8 NGCwWlNCeG:ydH;zbZMhSXO|YYm= NWraXJZ[OTd{L{K1NEBvVQ>? NILk[2g4\A>? MljXSG1UVw>? Mon5bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NHTUdYczPTByOUK5OS=>
SU-DHL-4 M3j3fGFxd3C2b4Ppd{BCe3OjeR?= M1vCOVE4Oi9{NUCgcm0> M4WzV|dl M{\udWROW09? NFHnUWxqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NUTjZohkOjVyMEmyPVU>
SU-DHL-10 M1LZWmFxd3C2b4Ppd{BCe3OjeR?= Ml;BNVczNzJ3MDDuUS=> NYPwTWg5P2R? MULEUXNQ MkHWbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MUmyOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice bearing NMC 797 xenografts
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Target Protein Ligand Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID